Substance use in sexual minority youth: prevalence in an urban cohort.

Addiction Adolescents Drug use LGBTQ Sexual minority youth

Journal

Child and adolescent psychiatry and mental health
ISSN: 1753-2000
Titre abrégé: Child Adolesc Psychiatry Ment Health
Pays: England
ID NLM: 101297974

Informations de publication

Date de publication:
16 Sep 2023
Historique:
received: 21 07 2023
accepted: 08 09 2023
medline: 17 9 2023
pubmed: 17 9 2023
entrez: 16 9 2023
Statut: epublish

Résumé

Little comparative data on substance use (SU) between sexual minority youth (SMY) and heterosexual youth (HET) is available. This study compares the prevalence of SU in an urban cohort between SMY and HET and evaluates demographic and psychosocial predictors of SU. Data came from a prospective-longitudinal cohort study in an urban setting (N = 1297). SU and psychosocial variables such as internalizing symptoms, self-control, sensation-seeking, bullying-victimization, subjective stress, leisure activities, and peer influences were assessed with self-reports at age 17 and 20. SU was stratified by sex and sexual attraction, and the groups were compared using regression models, with demographic and psychosocial variables included as covariates. SMY- and HET-youth displayed differences in a number of psychosocial variables. Overall, SMY- and HET-youth differed in their 12-months prevalence of SU: At age 17, SMY-females had significantly higher rates of SU than HET-females for cannabis (aOR = 2.14, p = 0.04), ecstasy/MDMA (aOR = 4.29, p = 0.01), and hallucinogens (aOR = 5.59, p = 0.02). At age 20, SMY-females had significantly higher rates of SU than HET-females for tobacco (aOR = 2.06, p = 0.03), cannabis (aOR = 2.24, p = 0.004), ecstasy/MDMA (aOR = 3.93, p < 0.001), stimulants (aOR = 3.45, p = 0.002), and hallucinogens (aOR = 6.65, p < 0.001). SMY-males reported significantly lower rates for tobacco and cannabis than HET-males at age 17. At age 20, they reported significantly higher rates for the use of ecstasy/MDMA (aOR = 2.30, p = 0.04) and hallucinogens (aOR = 2.43, p = 0.03). Given that psychosocial variables were significant covariates of SMY-status and SU, our results underline the importance of accounting for these when explaining differences in SU between adolescents. While differentiation by sex is established in most studies, such standardized comparisons are lacking with regards to sexual identities. But knowledge about SU of SMY is critical for designing effective interventions. This is especially true for SMY-females: Thus, SU in SMY-females early in life needs to be explored more thoroughly and addressed with adequate prevention measures.

Sections du résumé

BACKGROUND BACKGROUND
Little comparative data on substance use (SU) between sexual minority youth (SMY) and heterosexual youth (HET) is available. This study compares the prevalence of SU in an urban cohort between SMY and HET and evaluates demographic and psychosocial predictors of SU.
METHODS METHODS
Data came from a prospective-longitudinal cohort study in an urban setting (N = 1297). SU and psychosocial variables such as internalizing symptoms, self-control, sensation-seeking, bullying-victimization, subjective stress, leisure activities, and peer influences were assessed with self-reports at age 17 and 20. SU was stratified by sex and sexual attraction, and the groups were compared using regression models, with demographic and psychosocial variables included as covariates.
RESULTS RESULTS
SMY- and HET-youth displayed differences in a number of psychosocial variables. Overall, SMY- and HET-youth differed in their 12-months prevalence of SU: At age 17, SMY-females had significantly higher rates of SU than HET-females for cannabis (aOR = 2.14, p = 0.04), ecstasy/MDMA (aOR = 4.29, p = 0.01), and hallucinogens (aOR = 5.59, p = 0.02). At age 20, SMY-females had significantly higher rates of SU than HET-females for tobacco (aOR = 2.06, p = 0.03), cannabis (aOR = 2.24, p = 0.004), ecstasy/MDMA (aOR = 3.93, p < 0.001), stimulants (aOR = 3.45, p = 0.002), and hallucinogens (aOR = 6.65, p < 0.001). SMY-males reported significantly lower rates for tobacco and cannabis than HET-males at age 17. At age 20, they reported significantly higher rates for the use of ecstasy/MDMA (aOR = 2.30, p = 0.04) and hallucinogens (aOR = 2.43, p = 0.03).
CONCLUSIONS CONCLUSIONS
Given that psychosocial variables were significant covariates of SMY-status and SU, our results underline the importance of accounting for these when explaining differences in SU between adolescents. While differentiation by sex is established in most studies, such standardized comparisons are lacking with regards to sexual identities. But knowledge about SU of SMY is critical for designing effective interventions. This is especially true for SMY-females: Thus, SU in SMY-females early in life needs to be explored more thoroughly and addressed with adequate prevention measures.

Identifiants

pubmed: 37716977
doi: 10.1186/s13034-023-00657-0
pii: 10.1186/s13034-023-00657-0
pmc: PMC10505308
doi:

Types de publication

Journal Article

Langues

eng

Pagination

109

Subventions

Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 10FI14_198052
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 10FI14_198052
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 10FI14_198052
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 10FI14_198052
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 10FI14_198052
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 10FI14_198052

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Int J Drug Policy. 2018 May;55:180-182
pubmed: 29661572
J Dev Life Course Criminol. 2022;8(1):151-171
pubmed: 35223378
Drug Alcohol Rev. 2015 Jul;34(4):358-65
pubmed: 24890312
Curr Opin Psychol. 2019 Dec;30:123-127
pubmed: 31202102
Addiction. 2008 Apr;103(4):546-56
pubmed: 18339100
Aust N Z J Public Health. 2021 Feb;45(1):20-25
pubmed: 33252815
Harm Reduct J. 2016 Dec 9;13(1):36
pubmed: 27938393
J Adolesc Health. 2018 Jun;62(6):688-700
pubmed: 29241986
Front Public Health. 2022 Nov 15;10:997730
pubmed: 36457321
Subst Use Misuse. 2018 Jun 7;53(7):1221-1228
pubmed: 29236561
Drug Alcohol Depend. 2017 Sep 1;178:355-362
pubmed: 28692946
Eur Addict Res. 2022;28(3):186-198
pubmed: 34864731
Health Econ. 2022 Jan;31(1):42-56
pubmed: 34628683
Psychol Bull. 2003 Sep;129(5):674-697
pubmed: 12956539
LGBT Health. 2020 Feb/Mar;7(2):82-89
pubmed: 31985327
Subst Use Misuse. 2018 Jan 2;53(1):170-175
pubmed: 28777685
Addict Behav. 2021 Jan;112:106609
pubmed: 32861992
Int J Drug Policy. 2021 Jul;93:103187
pubmed: 33771421
Ann Behav Med. 2017 Aug;51(4):567-577
pubmed: 28124182
Int J Environ Res Public Health. 2022 Sep 25;19(19):
pubmed: 36231424
Drug Alcohol Depend. 2019 Jan 1;194:410-429
pubmed: 30502543
Lancet Psychiatry. 2016 Mar;3(3):251-64
pubmed: 26905480
Addict Behav. 2018 Jun;81:167-174
pubmed: 29395187
Int J Drug Policy. 2022 Oct;108:103808
pubmed: 35914477
J Psychoactive Drugs. 2023 Jul-Aug;55(3):268-273
pubmed: 35616605
Assessment. 2019 Oct;26(7):1234-1245
pubmed: 28758417
J Abnorm Child Psychol. 2016 May;44(4):663-75
pubmed: 26370547
Neurobiol Stress. 2018 Dec 27;10:100146
pubmed: 30937352
J Atten Disord. 2020 Nov;24(13):1796-1806
pubmed: 28440106
Int J Drug Policy. 2018 May;55:169-179
pubmed: 29429865
Int J Drug Policy. 2020 Mar;77:102670
pubmed: 32143965
Addiction. 2016 Sep;111(9):1599-606
pubmed: 27018582
Psychol Sex Orientat Gend Divers. 2016 Sep;3(3):357-366
pubmed: 27713906
Arch Sex Behav. 2022 Apr;51(3):1495-1501
pubmed: 35142972
Am J Prev Med. 2017 Oct;53(4):547-558
pubmed: 28826950
J Public Health (Oxf). 2017 Sep 1;39(3):532-541
pubmed: 27519959
Arch Pediatr. 2020 Nov;27(8):448-451
pubmed: 33011028
Drug Alcohol Depend. 2021 Nov 1;228:109063
pubmed: 34601277
Front Behav Neurosci. 2022 Jan 27;15:797473
pubmed: 35153693
World J Virol. 2022 Jul 25;11(4):208-211
pubmed: 36159612
J Am Acad Child Adolesc Psychiatry. 2023 Jul;62(7):791-804
pubmed: 36731790
Nicotine Tob Res. 2017 Nov 07;19(12):1408-1417
pubmed: 27613909
Soc Psychiatry Psychiatr Epidemiol. 2007 May;42(5):414-20
pubmed: 17450453
Psychol Med. 2015 May;45(7):1551-63
pubmed: 25534496
BMC Public Health. 2021 May 5;21(1):863
pubmed: 33952247
Psychiatr Serv. 2020 Feb 1;71(2):112-120
pubmed: 31640522
Assessment. 2021 Jan;28(1):128-140
pubmed: 31280595
Child Adolesc Psychiatry Ment Health. 2022 Mar 14;16(1):21
pubmed: 35287691

Auteurs

Florian Vock (F)

Swiss AIDS Federation, Zurich, Switzerland. florianvock@icloud.com.

Lydia Johnson-Ferguson (L)

Jacobs Center for Productive Youth Development, University of Zurich, Zurich, Switzerland.
Department of Psychology, Clinical and Developmental Psychology, University of Zurich, Zurich, Switzerland.
Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital of the University of Zurich, Zurich, Switzerland.

Laura Bechtiger (L)

Jacobs Center for Productive Youth Development, University of Zurich, Zurich, Switzerland.
Department of Psychology, Clinical and Developmental Psychology, University of Zurich, Zurich, Switzerland.

Niklaus Stulz (N)

Integrated Psychiatric Services Psychiatry Winterthur - Zürcher Unterland, Winterthur, Switzerland.

Joh von Felten (J)

Milchjugend, LGBTQ+ Youth Organization, Zurich, Switzerland.

Manuel Eisner (M)

Jacobs Center for Productive Youth Development, University of Zurich, Zurich, Switzerland.
Institute of Criminology, University of Cambridge, Cambridge, UK.

Urs Hepp (U)

Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Denis Ribeaud (D)

Jacobs Center for Productive Youth Development, University of Zurich, Zurich, Switzerland.

Lilly Shanahan (L)

Jacobs Center for Productive Youth Development, University of Zurich, Zurich, Switzerland.
Department of Psychology, Clinical and Developmental Psychology, University of Zurich, Zurich, Switzerland.

Boris B Quednow (BB)

Jacobs Center for Productive Youth Development, University of Zurich, Zurich, Switzerland.
Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital of the University of Zurich, Zurich, Switzerland.

Classifications MeSH